Literature DB >> 18475635

Interleukin-2 receptor beta chain as a possible target for low doses of mafosfamide.

A Pukhalsky1, A Toptygina, S Khaidukov.   

Abstract

The 7-day cytotoxic lymphocytes (CTL) induced in mixed lymphocyte culture express only the chain of the interleukin-2 receptor (IL-2R). In the present study this fact has been confirmed in a murine semi-allogeneic system. The ability of low doses of mafosfamide (Mf) to affect IL-2-induced CTL proliferation has been demonstrated. It was also shown that IL-2 activated resting suppressor cells. The pretreatment of the suppressor cells with either monoclonal antibodies (mAbs) against the p75 chain of IL-2R, or with Mf abolished the suppressive effect of these cells. No restoration of the proliferative response occurred when the anti-IL-2Ralpha mAb had been used. Flow cytometry analysis of 7-day CTL was carried out with mAbs against the alpha and beta chains of IL-2R. CTL treatment with Mf inhibited anti-IL-2Rbeta mAb binding. It may be assumed that the anti-proliferative effects of Mf which have been demonstrated in this paper, were a result of blocking the IL-2R beta chain.

Entities:  

Year:  1995        PMID: 18475635      PMCID: PMC2365629          DOI: 10.1155/S0962935195000287

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  18 in total

1.  [Sensitivity of the splenic cells of different mouse strains to the antiproliferative action of alkylating compounds].

Authors:  A L Pukhal'skiĭ; A P Mezhneva; L A Pevnitskiĭ
Journal:  Biull Eksp Biol Med       Date:  1988-02

2.  Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNA's.

Authors:  M Hatakeyama; M Tsudo; S Minamoto; T Kono; T Doi; T Miyata; M Miyasaka; T Taniguchi
Journal:  Science       Date:  1989-05-05       Impact factor: 47.728

3.  Differential expression of the IL-2 receptor subunits, p55 and p75 on various populations of primary peripheral blood mononuclear cells.

Authors:  Y Ohashi; T Takeshita; K Nagata; S Mori; K Sugamura
Journal:  J Immunol       Date:  1989-12-01       Impact factor: 5.422

4.  Effect of cyclosporin A and dexamethasone on interleukin 2 receptor gene expression.

Authors:  J C Reed; A H Abidi; J D Alpers; R G Hoover; R J Robb; P C Nowell
Journal:  J Immunol       Date:  1986-07-01       Impact factor: 5.422

5.  Cyclophosphamide and abrogation of tumor-induced suppressor T cell activity.

Authors:  S K Hoover; S K Barrett; T M Turk; T C Lee; H D Bear
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

6.  A restricted cytoplasmic region of IL-2 receptor beta chain is essential for growth signal transduction but not for ligand binding and internalization.

Authors:  M Hatakeyama; H Mori; T Doi; T Taniguchi
Journal:  Cell       Date:  1989-12-01       Impact factor: 41.582

7.  Molecular cloning and expression of cDNAs for the human interleukin-2 receptor.

Authors:  W J Leonard; J M Depper; G R Crabtree; S Rudikoff; J Pumphrey; R J Robb; M Krönke; P B Svetlik; N J Peffer; T A Waldmann
Journal:  Nature       Date:  1984 Oct 18-24       Impact factor: 49.962

8.  A novel monoclonal antibody against murine IL-2 receptor beta-chain. Characterization of receptor expression in normal lymphoid cells and EL-4 cells.

Authors:  T Tanaka; M Tsudo; H Karasuyama; F Kitamura; T Kono; M Hatakeyama; T Taniguchi; M Miyasaka
Journal:  J Immunol       Date:  1991-10-01       Impact factor: 5.422

9.  Cyclosporin A and prednisolone do not inhibit the expression of high-affinity receptors for interleukin 2.

Authors:  E Bloemena; M H Van Oers; S Weinreich; P T Schellekens
Journal:  Clin Exp Immunol       Date:  1988-02       Impact factor: 4.330

10.  Cross-linking of DNA in L1210 cells and nuclei treated with cyclophosphamide and phosphoramide mustard.

Authors:  Y A Surya; J M Rosenfeld; B L Hillcoat
Journal:  Cancer Treat Rep       Date:  1978-01
View more
  1 in total

1.  Cognitive disorders in mice: cytokine signaling pathways as therapeutic targets.

Authors:  Alexander Pukhalsky; Galina Shmarina; Vladimir Alioshkin
Journal:  OMICS       Date:  2012 Jan-Feb
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.